These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32012202)

  • 21. Distinct disease-modifying therapies are associated with different blood immune cell profiles in people with relapsing-remitting multiple sclerosis.
    Canto-Gomes J; Boleixa D; Teixeira C; Martins da Silva A; González-Suárez I; Cerqueira J; Correia-Neves M; Nobrega C
    Int Immunopharmacol; 2024 Apr; 131():111826. PubMed ID: 38461632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-β1 and fingolimod therapy.
    Acar NP; Tuncer A; Ozkazanc D; Ozbay FG; Karaosmanoglu B; Goksen S; Sayat G; Taskiran EZ; Esendagli G; Karabudak R
    J Neuroimmunol; 2020 Oct; 347():577353. PubMed ID: 32745802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent varicella following steroids and fingolimod in a Multiple Sclerosis patient.
    Ferraro D; De Biasi S; Vitetta F; Simone AM; Federzoni L; Borghi V; Cossarizza A; Nichelli PF; Sola P
    J Neuroimmune Pharmacol; 2013 Dec; 8(5):1059-61. PubMed ID: 24163092
    [No Abstract]   [Full Text] [Related]  

  • 24. Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis.
    Haas J; Schwarz A; Korporal-Kunke M; Jarius S; Wiendl H; Kieseier BC; Wildemann B
    Mult Scler; 2015 Oct; 21(12):1521-32. PubMed ID: 25583847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-Resolution Expression Profiling of Peripheral Blood CD8
    Roch L; Hecker M; Friess J; Angerer IC; Koczan D; Fitzner B; Schröder I; Flechtner K; Thiesen HJ; Meister S; Winkelmann A; Zettl UK
    Mol Neurobiol; 2017 Sep; 54(7):5511-5525. PubMed ID: 27631876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.
    Ghadiri M; Fitz-Gerald L; Rezk A; Li R; Nyirenda M; Haegert D; Giacomini PS; Bar-Or A; Antel J
    Mult Scler; 2017 Aug; 23(9):1225-1232. PubMed ID: 28749311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
    Blumenfeld S; Staun-Ram E; Miller A
    J Autoimmun; 2016 Jun; 70():40-51. PubMed ID: 27055778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy markedly reduces B cells but not T cells and NK cells in patients with cancer.
    Waidhauser J; Schuh A; Trepel M; Schmälter AK; Rank A
    Cancer Immunol Immunother; 2020 Jan; 69(1):147-157. PubMed ID: 31900508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low Memory T Cells Blood Counts and High Naïve Regulatory T Cells Percentage at Relapsing Remitting Multiple Sclerosis Diagnosis.
    Canto-Gomes J; Silva CS; Rb-Silva R; Boleixa D; da Silva AM; Cheynier R; Costa P; González-Suárez I; Correia-Neves M; Cerqueira JJ; Nobrega C
    Front Immunol; 2022; 13():901165. PubMed ID: 35711452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis.
    Ghadiri M; Rezk A; Li R; Evans A; Giacomini PS; Barnett MH; Antel J; Bar-Or A
    Sci Rep; 2020 Jan; 10(1):356. PubMed ID: 31941953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
    Kemmerer CL; Pernpeintner V; Ruschil C; Abdelhak A; Scholl M; Ziemann U; Krumbholz M; Hemmer B; Kowarik MC
    PLoS One; 2020; 15(7):e0235449. PubMed ID: 32716916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis.
    Hunter SF; Bowen JD; Reder AT
    CNS Drugs; 2016 Feb; 30(2):135-47. PubMed ID: 26715391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
    Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
    Front Immunol; 2018; 9():1097. PubMed ID: 29896193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microarray data of transcriptome shifts in blood cell subsets during S1P receptor modulator therapy.
    Koczan D; Fitzner B; Zettl UK; Hecker M
    Sci Data; 2018 Jul; 5():180145. PubMed ID: 30040082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
    Kowarik MC; Pellkofer HL; Cepok S; Korn T; Kümpfel T; Buck D; Hohlfeld R; Berthele A; Hemmer B
    Neurology; 2011 Apr; 76(14):1214-21. PubMed ID: 21464424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IFNbeta-1a therapy for multiple sclerosis expands regulatory CD8+ T cells and decreases memory CD8+ subset: a longitudinal 1-year study.
    Aristimuño C; de Andrés C; Bartolomé M; de las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
    Clin Immunol; 2010 Feb; 134(2):148-57. PubMed ID: 19900844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
    Longbrake EE; Ramsbottom MJ; Cantoni C; Ghezzi L; Cross AH; Piccio L
    Mult Scler; 2016 Jul; 22(8):1061-1070. PubMed ID: 26459150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta.
    Saraste M; Irjala H; Airas L
    Neurol Sci; 2007 Jun; 28(3):121-6. PubMed ID: 17603762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients.
    Johnson TA; Evans BL; Durafourt BA; Blain M; Lapierre Y; Bar-Or A; Antel JP
    J Immunol; 2011 Jul; 187(1):570-9. PubMed ID: 21622858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients.
    Quirant-Sánchez B; Hervás-García JV; Teniente-Serra A; Brieva L; Moral-Torres E; Cano A; Munteis E; Mansilla MJ; Presas-Rodriguez S; Navarro-Barriuso J; Ramo-Tello C; Martínez-Cáceres EM
    CNS Neurosci Ther; 2018 Dec; 24(12):1175-1184. PubMed ID: 29656444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.